Frontiers in Oncology (Mar 2023)
Editorial: Advances in the treatment of chronic myeloid leukemia
- Ahmet Emre Eşkazan,
- Chung H. Kok,
- Chung H. Kok,
- Chung H. Kok,
- David Yeung,
- David Yeung,
- David Yeung,
- David Yeung,
- Jignesh Dalal,
- Jignesh Dalal,
- Mario Tiribelli,
- Mario Tiribelli
Affiliations
- Ahmet Emre Eşkazan
- Division of Hematology, Department of Internal Medicine, Cerrahpaşa Faculty of Medicine, Istanbul University-Cerrahpaşa, Istanbul, Türkiye
- Chung H. Kok
- Precision Cancer Medicine Theme, South Australian Health & Medical Research Institute (SAHMRI), Adelaide, SA, Australia
- Chung H. Kok
- Adelaide Medical School, University of Adelaide, Adelaide, SA, Australia
- Chung H. Kok
- Centre for Cancer Biology, University of South Australia, Adelaide, SA, Australia
- David Yeung
- Precision Cancer Medicine Theme, South Australian Health & Medical Research Institute (SAHMRI), Adelaide, SA, Australia
- David Yeung
- Adelaide Medical School, University of Adelaide, Adelaide, SA, Australia
- David Yeung
- Centre for Cancer Biology, University of South Australia, Adelaide, SA, Australia
- David Yeung
- Department of Haematology, Royal Adelaide Hospital and SA Pathology, Adelaide, SA, Australia
- Jignesh Dalal
- Division of Hematology and Bone Marrow Transplant, Rainbow Babies and Children’s Hospital, OH, United States
- Jignesh Dalal
- Case Western Reserve University, Cleveland, OH, United States
- Mario Tiribelli
- Division of Hematology and Bone Marrow Transplant, Azienda Sanitaria Universitaria Friuli Centrale (ASUFC) – Udine Hospital, Udine, Italy
- Mario Tiribelli
- Department of Medicine, University of Udine, Udine, Italy
- DOI
- https://doi.org/10.3389/fonc.2023.1166588
- Journal volume & issue
-
Vol. 13
Abstract
No abstracts available.Keywords
- adverse event
- arterial occlusive event
- BCR::ABL1 transcript
- COVID-19
- quality of life
- stem cell transplantation